SCHEMBL7496797

SCHEMBL7496797

CN(C)CCOc1ccc(N/C(=C2\C(=O)Nc3ccc(S(=O)(=O)Nc4ccccc4)cc32)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1B Q00975 6/20 0.48
▸ BRD4 O60885 3/20 0.47
▸ MGAT2 Q10469 4/20 0.45
▸ MGAT1 P26572 2/20 0.43
▸ MGAT3 Q09327 1/20 0.43
▸ CACNA1H O95180 4/20 0.41
▸ PSEN1 P49768 1/20 0.41
▸ PSEN2 P49810 1/20 0.41
▸ APH1B Q8WW43 1/20 0.41
▸ NCSTN Q92542 1/20 0.41
▸ APH1A Q96BI3 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ LIMK2 P53671 1/20 0.41
▸ BRD2 P25440 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7496800 1.00 CACNA1B (0.48) CACNA1BBRD4MGAT2MGAT1MGAT3
SCHEMBL7495974 0.96 CACNA1B (0.54) CACNA1BBRD4MGAT2MGAT1MGAT3
SCHEMBL7495963 0.96 CACNA1B (0.54) CACNA1BBRD4MGAT2MGAT1MGAT3
SCHEMBL7499109 0.89 MAPT (0.52) BRD4MGAT2MGAT1MGAT3LMNA
SCHEMBL7499102 0.89 MAPT (0.52) BRD4MGAT2MGAT1MGAT3LMNA
SCHEMBL7493556 0.86 BRD4 (0.62) BRD4MGAT2MGAT1MGAT3BRD2
SCHEMBL7493564 0.86 BRD4 (0.62) BRD4MGAT2MGAT1MGAT3BRD2
SCHEMBL7497322 0.85 MGAT2 (0.55) BRD4MGAT2MGAT1MGAT3BRD2
SCHEMBL7488835 0.85 MGAT2 (0.55) BRD4MGAT2MGAT1MGAT3BRD2
SCHEMBL7494041 0.85 BRD4 (0.45) BRD4MGAT2MGAT1MGAT3LIMK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224169-A2 PRODUCTION OF 5-SUBSTITUTED INDOLINONES AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma KG (DE) 2002-07-24 — — EP disclosed
WO-2001027080-A2 5-SUBSTITUTED INDOLINONES AND USE THEREOF AS KINASE AND CYCLIN/CDK COMPLEX INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 — — WO disclosed
Send feedback